<DOC>
	<DOC>NCT01332019</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy Study of Peginterferon Beta-1a</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Must have completed the study treatment and visit schedule through Week 96 in Study 105MS301 (NCT00906399). Key Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study 105MS301 (NCT00906399). Subjects with any clinically significant laboratory abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease Pregnant or nursing women. NOTE: Other protocoldefined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Subcutaneous</keyword>
	<keyword>Extension</keyword>
	<keyword>Interferon</keyword>
	<keyword>MS</keyword>
	<keyword>PEGylated</keyword>
	<keyword>Injectable</keyword>
	<keyword>SC</keyword>
	<keyword>PEG</keyword>
	<keyword>peginterferon beta-1a</keyword>
	<keyword>Relapsing</keyword>
</DOC>